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Conclusions: GAFCHROMIC® MD-V2-55 radiochromic films has been an 
useful tool to know real dose administration along the breast target 
and to understand some abnormal MOSFET reading. 
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Purpose/Objective: To report outcomes for patients treated with 
salvage surgical resection and intraoperative radiotherapy (IORT) for 
residual or recurrent squamous cell carcinoma (SCC) of the anus after 
primary chemoradiotherapy (CRT). 
Materials and Methods: The prospective radiation oncology 
department IORT database was searched for patients treated with 
surgery and IORT for anal SCC. Thirty-two patients treated between 
1993 and 2012 were identified. All patients had previously received 
primary concurrent CRT and had residual or recurrent disease based 
on clinical findings and/or tissue confirmation. All patients with 
recurrent disease received pre-operative, limited field external beam 
re-irradiation (median dose 30 Gray) and concurrent chemotherapy. 
IORT was utilized due to concern that salvage surgery alone would be 
unlikely to remove all gross and/or microscopic disease. Treatment-
related adverse events were classified according to the National 
Cancer Institute – Common Toxicity Criteria Adverse Events (AEs). 
Overall survival (OS), disease-free survival (DFS), central failure (CF; 
within the IORT field), local-regional failure (LRF; tumor bed or 
draining lymphatics), and distant failure (DF) were estimated using 
the Kaplan-Meier technique. 
Results: Median age at IORT was 53 years (range 34-87). Twenty-six 
patients (81%) were female. Salvage treatment was performed for 
residual disease after CRT (n=9), 1st recurrence after CRT (n=17), or 
2nd recurrence after CRT and salvage abdominal-perineal resection 
(APR, n=6). APR was a component of the multimodality salvage 
attempt in 22 patients. Extent of surgical resection was R0 (negative 
margins, n=16), R1 (microscopic residual, n=13), or R2 (macroscopic 
residual, n=3). IORT was delivered with electron beams (n=31) or high-
dose rate brachytherapy (n=1). Median IORT dose was 12.5 Gray 
(range 7.5 – 20). Median length of hospital stay was 9 days.  
Nine patients (28%) were alive at last follow-up. The median follow-up 
duration was 1.6 years for all patients and 6.3 years for living 
patients. Mortality at 30 days after surgery and IORT was 0%. Fifteen 
patients (47%) experienced a total of 16 grade 3 treatment-related 
AEs. The most common Grade 3 AEs were wound complications (n=6), 
bowel obstruction (n=5), and ureteral obstruction (n=3). There were 
no grade 4 or 5 AEs. The 5-year estimates of OS and DFS were 23% and 
17%, respectively. The 5-year estimates of CF, LRF, and DF were 26%, 
64%, and 48%, respectively. 
Conclusions: In this heavily pre-treated, high-risk patient population, 
aggressive salvage surgery and IORT was associated with long-term 
survival in a small, but significant subset of patients. 
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Purpose/Objective: Breast conserving therapy (BCT) with 
complementary radiotherapy is an effective alternative for 
mastectomy what was confirmed by comparable survivals in 20-years 
observations of randomized trials. Standard procedure after BCT is 
whole breast irradiation with higher dose on tumor bed. The dose 
escalation may be proceeded by brachytherapy, intraoperative 
radiotherapy (IORT) and conformal radiotherapy (3D-CRT) from 
external beams.  
The purpose of this paper was to report four years of IORT during 
breast-conserving surgery (BCS) as a tumor bed boost using high 
energy electrons. 
Materials and Methods: Between May 2008 and November 2012 in 255 
breast cancers treated IORT as a tumor bed boost was applied using 
electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). IORT 
boost (10 Gy) was followed by whole-breast external beam 
radiotherapy (EBRT) – 25 fractions 2.0 Gy each or 15 fractions of 2.7 
Gy each for patients registered in multi-center HIOB trial 
(Hypofractionated Whole-Breast Irradiation preceded by Intra-
Operative Radiotherapy with Electrons as anticipated Boost).  
150 patients were analyzed to evaluate the risk of local failure after 
BCT, IORT boost and EBRT with minimal observation period of 1 year. 
The clinical profile is presented in table. 
After tumor excision, shielding plate was placed on a patient's chest 
wall, underneath breast tissues. Appropriate applicator size and tip 
bevel were chosen to cover whole tumor bed with specified IORT 
margins. Electron energy was precisely chosen to assure homogeneous 
dose distribution and to deliver 10 Gy to the 90% isodose, which 
reaches shielding plate surface, independently of tissue thickness. 




Results: There was no local failure in analyzed group of patients. 
Median age of treated women was 58 years (35 to 77). Patients were 
treated using all available electron beam energies: 6 MeV was used in 
52% cases but also 9 MeV, 4 MeV and 12 MeV (33%, 13% and 2% cases 
respectively) were used for treatment. In 51% cases applicator size 
(which is related to the tumor bedsize) was 5 cm in diameter. The 
smallest used applicator was 4 cm in diameter(27% cases) and the 
largest one was 7 cm (1%). This results in average planning target 
volume - PTV (volume of tissue encompassed by the 90% isodose line) 
of35.31 cc ranging from 12.00 cc to 75.35 cc. In 56% cases no bolus 
was needed; 0.5 cm bolus was used in 83 cases (33%). In all treatment 
procedures aluminium-lead shielding plates were used, 82% of which 
were 0.5 cm thick. The thickness of irradiated breast gland was less 
than 1.5 cm in half of treated cases and between 1.5 cm and 2 cm in 
40%. Breast gland thicker than 2.5 cm was irradiated only in 3% of all 
treated cases (figure). 
 
Conclusions: Intraoperative radiotherapy as a tumor bed boost during 
breast-conserving surgery for breast cancer using high-energy 
electrons from a mobile linear accelerator is proved to be effective 
and perspective treatment procedure. 
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